GlassScriptPhysician profile
Joel A Adkisson
NPI 1861468548
$1,862.11
in general payments reported to CMS, 2019-2025
29 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $154 · 2021: $220 · 2022: $162 · 2023: $277 · 2024: $445 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $329.82 | 2023-2025 | Azstarys |
| Abbvie INC. | $249.51 | 2021-2025 | Botox |
| Amarin Pharma, INC. | $130.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $126.85 | 2020-2025 | Airsupra |
| Pfizer INC. | $96.29 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.02 | 2023-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $93.77 | 2019-2020 | |
| Astellas Pharma US INC | $88.43 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $57.45 | 2022-2024 | Rexulti |
| Tris Pharma INC | $53.16 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $47.75 | 2024-2025 | Rexulti |
| Allergan, INC. | $44.47 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.99 | 2019-2024 | Jardiance |
| Almatica Pharma LLC | $39.65 | 2023-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Halozyme INC | $38.13 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.08 | 2020-2021 | |
| Lilly USA, LLC | $32.64 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $30.10 | 2021-2022 | |
| Novo Nordisk INC | $29.00 | 2019 | |
| Alkermes, INC. | $28.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.59 | 2022 | |
| Antares Pharma, INC. | $23.60 | 2020 | |
| Amgen INC. | $21.70 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.05 | 2023 | Xyosted, Qelbree, Tlando |
| Sanofi Pasteur INC. | $18.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2022 | |
| Forte Bio-Pharma LLC | $16.09 | 2025 | Prolate, Nalocet, Tanlor |
| Horizon Therapeutics Plc | $15.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Adkisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.